Small, mid-size biotechs could see M&A action in H2


As many large pharmas continue to deal with upcoming patent cliffs that will impact sales of key drugs, it could spur additional dealmaking for small and mid-size biotechs to make up for the loss of revenue.

These biotechs “will receive significant

Source link

Related Articles

Back to top button